keyword
https://read.qxmd.com/read/38513727/an-analysis-of-multidrug-multicomponent-crystals-as-tools-for-drug-development
#1
REVIEW
Oisín N Kavanagh
In a typical tablet or capsule formulation, the active drug is often present as a crystalline solid. This solid emerges from the relationships between the individual atoms within the crystal, which confer a distinct set of physical properties. Thus, the packing arrangement of the individual drug molecules within these crystals can be modified by crystal engineering to modulate their properties. Crystal engineering has also seen teams arrange multiple drug molecules within the same crystal, which has resulted in dramatic improvements to drug properties in the lab...
March 19, 2024: Journal of Controlled Release
https://read.qxmd.com/read/38438119/association-between-use-of-sodium-glucose-cotransporter-2-inhibitors-or-angiotensin-receptor-neprilysin-inhibitor-and-the-risk-of-atherosclerotic-cardiovascular-disease-with-coexisting-diabetes-and-heart-failure
#2
JOURNAL ARTICLE
Ya-Wen Lin, Chun-Hsiang Lin, Cheng-Li Lin, Che-Huei Lin, Ming-Hung Lin
PURPOSE: This study was to investigate the association between the use of Sodium-glucose Cotransporter-2 inhibitors (SGLT2i) or angiotensin receptor-neprilysin inhibitor (ARNI; ie, Sacubitril + valsartan, Product name ENTRESTO) and the risk of atherosclerotic cardiovascular disease (ASCVD) in patients with coexisting diabetes and heart failure. Specifically, the study compared outcomes between patients using SGLT2i or valsartan + sacubitril and those not using these medications...
2024: Journal of Cardiovascular Pharmacology and Therapeutics
https://read.qxmd.com/read/38366299/preclinical-evaluation-of-new-grpr-antagonists-with-improved-metabolic-stability-for-radiotheranostic-use-in-oncology
#3
JOURNAL ARTICLE
Panagiotis Kanellopoulos, Adam Mattsson, Ayman Abouzayed, Karim Obeid, Berthold A Nock, Vladimir Tolmachev, Theodosia Maina, Anna Orlova
BACKGROUND: The gastrin-releasing peptide receptor (GRPR) has been extensively studied as a biomolecular target for peptide-based radiotheranostics. However, the lack of metabolic stability and the rapid clearance of peptide radioligands, including radiolabeled GRPR-antagonists, often impede clinical application. Aiming at circumventing these drawbacks, we have designed three new GRPR-antagonist radioligands using [99m Tc]Tc-DB15 ([99m Tc]Tc-N4 -AMA-DIG-D Phe-Gln-Trp-Ala-Val-Sar-His-Leu-NHEt; AMA: p-aminomethylaniline; DIG: diglycolate) as a motif, due to its high GRPR-affinity and stability to neprilysin (NEP)...
February 16, 2024: EJNMMI Radiopharmacy and Chemistry
https://read.qxmd.com/read/38305596/knowledge-domain-and-emerging-trends-in-sacubitril-valsartan-study-from-2008-to-2023-a-visualized-conclusive-analysis-based-on-novel-scientometric-tools
#4
JOURNAL ARTICLE
X-C Zhao, L Huang, J-C Rong, B-H Lu
OBJECTIVE: This study aimed to determine the evolution of sacubitril-valsartan research and analyze the publications quantitatively and qualitatively. MATERIALS AND METHODS: We used the bibliometric method and a combination of CiteSpace_6.1.6 and VOSviewer_1.6.18 to identify top authors, countries, institutions, co-cited articles, co-cited journals, keywords, and trends. This study prioritized key aspects in the existing global research on Entresto (Sacubitril/Valsartan) to assess our depth of knowledge in this field and identify potential insights...
January 2024: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/38094382/retracted-effects-of-metoprolol-succinate-combined-with-entresto-on-cardiac-function-indexes-and-coagulation-function-in-patients-with-congestive-heart-failure
#5
Computational And Mathematical Methods In Medicine
[This retracts the article DOI: 10.1155/2022/9765884.].
2023: Computational and Mathematical Methods in Medicine
https://read.qxmd.com/read/38090453/sacubitril-valsartan-in-the-treatment-of-heart-failure-with-reduced-ejection-fraction-focusing-on-the-impact-on-the-quality-of-life-a-systematic-review-and-meta-analysis-of-randomized-clinical-trials
#6
REVIEW
Priyadarshini Bhattacharjee, Zahid Khan
There exists a paucity of research data reported by analyses performed on randomized clinical trials (RCTs) that encompass quality of life (QOL) and the aftermath for patients suffering from heart failure with reduced ejection fraction (HFrEF). This systematic review and meta-analysis of randomized clinical trials (RCTs) have been done to evaluate the drug sacubitril/valsartan in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) with a clear focus on the effect it bestows on measures of physical exercise tolerance and quality of life...
November 2023: Curēus
https://read.qxmd.com/read/38059322/dapagliflozin-entresto-protected-kidney-from-renal-hypertension-via-downregulating-cell-stress-signaling-and-upregulating-sirt1-pgc-1%C3%AE-mfn2-medicated-mitochondrial-homeostasis
#7
JOURNAL ARTICLE
Sheung-Fat Ko, Chih-Chao Yang, Pei-Hsun Sung, Ben-Chung Cheng, Pei-Lin Shao, Yi-Ling Chen, Hon-Kan Yip
This study tested whether combined dapagliflozin and entresto would be superior to mere one therapy on protecting the residual renal function and integrity of kidney parenchyma in hypertensive kidney disease (HKD) rat. In vitro results showed that the protein expressions of oxidative-stress/mitochondrial-damaged (NOX-1/NOX-2/oxidized-protein/cytosolic-cytochrome-C)/apoptotic (mitochondrial-Bax/cleaved caspeases 3, 9)/cell-stress (p-ERK/p-JNK/p-p38) biomarkers were significantly increased in H2 O2 -treated NRK-52E cells than those of controls that were reversed by dapagliflozin or entresto treatment...
December 7, 2023: Experimental Biology and Medicine
https://read.qxmd.com/read/37948774/development-and-validation-of-a-sensitive-and-simple-lc-ms-ms-method-for-simultaneous-quantitation-of-valsartan-sacubitril-and-sacubitrilat-in-pediatric-population
#8
JOURNAL ARTICLE
Quancheng Yang, Peng Cao, Yi Lv, Hua Peng, Xuejia Zhai
Pediatric heart failure (HF) is an important clinical disease with high hospitalization rates, morbidity, mortality and medical costs. Sacubitril/valsartan (also known as Entresto), was approved for the treatment of adult HF and is recently used in pediatrics. However, clinical therapy on children is more challenging than adults, and the pharmacokinetics of Entresto in children are still largely unknown and urgently needed. Herein, we aim to develop a simple and sensitive analytic method to monitor Entresto in pediatric patients, which is of great importance for individualized safe medication in children...
October 30, 2023: Journal of Pharmaceutical and Biomedical Analysis
https://read.qxmd.com/read/37565914/sacubitril-valsartan-induced-liver-injury-a-case-report-and-literature-review
#9
JOURNAL ARTICLE
Ting Zhang, Jin-Lian Cai, Jie Yu
RATIONALE: Sacubitril/valsartan (Entresto) is the first drug approved for the treatment of symptomatic chronic heart failure with reduced ejection fraction in adult patients. There have been no reports of hepatotoxicity secondary to sacubitril/valsartan administration. Here, we report the first case of severe liver injury caused by sacubitril/valsartan. PATIENT CONCERNS: A 90-year-old female patient taking sacubitril/valsartan was admitted due to chronic heart failure...
August 11, 2023: Medicine (Baltimore)
https://read.qxmd.com/read/37502534/retracted-clinical-study-of-heart-failure-with-left-ventricular-ejection-fraction-regimen-treated-with-entresto
#10
Contrast Media Molecular Imaging
[This retracts the article DOI: 10.1155/2022/4164089.].
2023: Contrast Media & Molecular Imaging
https://read.qxmd.com/read/37388013/retracted-effect-of-entresto-on-clinical-symptoms-ventricular-remodeling-rehabilitation-and-hospitalization-rate-in-patients-with-both-acute-myocardial-infarction-and-acute-heart-failure
#11
Evidence-Based Complementary And Alternative Medicine
[This retracts the article DOI: 10.1155/2022/7650937.].
2023: Evidence-based Complementary and Alternative Medicine: ECAM
https://read.qxmd.com/read/37017901/different-doses-of-scubitril-valsartan-compared-with-olmesartan-in-patients-with-essential-hypertension-a-systematic-review-and-meta-analysis
#12
REVIEW
Amjaad Ibrahim Almarjan, Sara Abdulaziz Almarjan, Ahmed Taher Masoud
INTRODUCTION: Since sacubitril/valsartan (LCZ696) has neprilysin inhibition and angiotensin receptor-blocking properties, it is anticipated to have strong antihypertensive effects. However, there is not enough evidence to compare the safety and efficacy of sacubitril/valsartan to those of olmesartan in patients with hypertension. AIM: To compare the efficacy and safety of sacubitril/valsartan versus olmesartan in patients with hypertension. METHODS: This study follows the guidelines of the Cochrane Handbook...
April 5, 2023: High Blood Pressure & Cardiovascular Prevention: the Official Journal of the Italian Society of Hypertension
https://read.qxmd.com/read/36997815/sacubitril-valsartan-reverses-cardiac-structure-and-function-in-experimental-model-of-hypertension-induced-hypertrophic-cardiomyopathy
#13
JOURNAL ARTICLE
Jovana Jeremic, Natalia Govoruskina, Jovana Bradic, Isidora Milosavljevic, Ivan Srejovic, Vladimir Zivkovic, Nevena Jeremic, Tamara Nikolic Turnic, Irena Tanaskovic, Stefani Bolevich, Vladimir Jakovljevic, Sergey Bolevich, Marko N Zivanovic, Nduka Okwose, Dragana Seklic, Nevena Milivojevic, Jelena Grujic, Lazar Velicki, Guy MacGowan, Djordje G Jakovljevic, Nenad Filipovic
This study evaluated the effect of sacubtril/valsartan on cardiac remodeling, molecular and cellular adaptations in experimental (rat) model of hypertension-induced hypertrophic cardiomyopathy. Thirty Wistar Kyoto rats, 10 healthy (control) and 20 rats with confirmed hypertension-induced hypertrophic cardiomyopathy (HpCM), were used for this study. The HpCM group was further subdivided into untreated and sacubitril/valsartan-treated groups. Myocardial structure and function were assessed using echocardiography, Langendorff's isolated heart experiment, blood sampling and qualitative polymerase chain reaction...
March 30, 2023: Molecular and Cellular Biochemistry
https://read.qxmd.com/read/36871177/effect-of-sacubitril-valsartan-on-the-incidence-of-atrial-fibrillation-a-meta-analysis
#14
JOURNAL ARTICLE
Zoya Mohammad, Javaria Ahmad, Ali Sultan, Ashritha Penagaluri, Daniel Morin, Paari Dominic
INTRODUCTION: Sacubitril/valsartan reduces all-cause mortality in heart failure (HF) patients compared to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). ACEIs/ARBs have been shown to decrease the incidence of atrial fibrillation (AF). We hypothesized sacubitril-valsartan decreases the incidence of AF compared to ACEis/ARBs. METHODS: Clinicaltrials.gov was searched for trials by terms sacubitril/valsartan, entresto, sacubitril, valsartan...
April 2023: Journal of Cardiovascular Electrophysiology
https://read.qxmd.com/read/36785558/effect-of-emergency-percutaneous-coronary-intervention-combined-with-sacubitril-and-valsartan-on-the-cardiac-prognosis-in-patients-with-acute-myocardial-infarction
#15
JOURNAL ARTICLE
Hai Fan, Yuesong Wang, Xuezhong Wang, Xuebin Dong, Xuwu Shao, Fei Yang
PURPOSE: This study aimed to investigate the effect of emergency percutaneous coronary intervention (PCI) combined with sacubitril-valsartan (Entresto) on the cardiac prognosis in patients with acute myocardial infarction (AMI). PATIENTS AND METHODS: A total of 78 AMI patients who were treated in our hospital between January 2020 and September 2021 were included and randomly divided into treatment group and control group (n=39 per group). In the control group, patients were treated with primary PCI combined with irbesartan; in the treatment group, patients were treated with primary PCI combined with Entresto; pharmacotherapy lasted for 3 months...
2023: International Journal of General Medicine
https://read.qxmd.com/read/36729833/neprilysin-dependent-neuropeptide-y-cleavage-in-the-liver-promotes-fibrosis-by-blocking-npy-receptor-1
#16
JOURNAL ARTICLE
Cristina Ortiz, Sabine Klein, Winfried H Reul, Fernando Magdaleno, Stefanie Gröschl, Peter Dietrich, Robert Schierwagen, Frank E Uschner, Sandra Torres, Christoph Hieber, Caroline Meier, Nico Kraus, Olaf Tyc, Maximilian Brol, Stefan Zeuzem, Christoph Welsch, Marco Poglitsch, Claus Hellerbrand, Mercedes Alfonso-Prieto, Fabio Mira, Ulrich Auf dem Keller, Anja Tetzner, Andrew Moore, Thomas Walther, Jonel Trebicka
Development of liver fibrosis is paralleled by contraction of hepatic stellate cells (HSCs), the main profibrotic hepatic cells. Yet, little is known about the interplay of neprilysin (NEP) and its substrate neuropeptide Y (NPY), a potent enhancer of contraction, in liver fibrosis. We demonstrate that HSCs are the source of NEP. Importantly, NPY originates majorly from the splanchnic region and is cleaved by NEP in order to terminate contraction. Interestingly, NEP deficiency (Nep-/- ) showed less fibrosis but portal hypertension upon liver injury in two different fibrosis models in mice...
January 31, 2023: Cell Reports
https://read.qxmd.com/read/36601956/baseline-characteristics-of-pediatric-patients-with-heart-failure-due-to-systemic-left-ventricular-systolic-dysfunction-in-the-panorama-hf-trial
#17
RANDOMIZED CONTROLLED TRIAL
Robert Shaddy, Michael Burch, Paul F Kantor, Susan Solar-Yohay, Tania Garito, Sijia Zhang, Michele Kocun, Damien Bonnet
BACKGROUND: Sacubitril/valsartan has been approved for the management of heart failure (HF) with reduced ejection fraction in adults. PANORAMA-HF trial (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) investigated its effects on clinical outcomes in pediatric patients with HF. METHODS: PANORAMA-HF is a multicenter, Phase II/III study using an adaptive, seamless, 2-part design...
March 2023: Circulation. Heart Failure
https://read.qxmd.com/read/36419097/cooling-down-with-entresto-can-sacubitril-valsartan-combination-enhance-browning-more-than-coldness
#18
REVIEW
Marina Nikolic, Jovana Novakovic, Galina Ramenskaya, Vladimir Kokorekin, Nevena Jeremic, Vladimir Jakovljevic
BACKGROUND: It is a growing importance to induce a new treatment approach to encourage weight loss but also to improve maintenance of lost weight. It has been shown that promotion of brown adipose tissue (BAT) function or acquisition of BAT characteristics in white adipose tissue (terms referred as "browning") can be protective against obesity. MAIN TEXT: Amongst numerous established environmental influences on BAT activity, cold exposure is the best interested technique due to its not only effects on of BAT depots in proliferation process but also de novo differentiation of precursor cells via β-adrenergic receptor activation...
November 23, 2022: Diabetology & Metabolic Syndrome
https://read.qxmd.com/read/36368295/silicofcm-platform-multiscale-modeling-of-left-ventricle-from-echocardiographic-images-and-drug-influence-for-cardiomyopathy-disease
#19
JOURNAL ARTICLE
Nenad Filipovic, Tijana Sustersic, Miljan Milosevic, Bogdan Milicevic, Vladimir Simic, Momcilo Prodanovic, Srboljub Mijailovic, Milos Kojic
BACKGROUND AND OBJECTIVE: In silico clinical trials are the future of medicine and virtual testing and simulation are the future of medical engineering. The use of a computational platform can reduce costs and time required for developing new models of medical devices and drugs. The computational platform, which is one of the main results of the SILICOFCM project, was developed using state-of-the-art finite element modeling for macro simulation of fluid-structure interaction with micro modeling at the molecular level for drug interaction with the cardiac cells...
December 2022: Computer Methods and Programs in Biomedicine
https://read.qxmd.com/read/36359384/the-role-of-nf-%C3%AE%C2%BAb-and-bax-bcl-2-caspase-3-signaling-pathways-in-the-protective-effects-of-sacubitril-valsartan-entresto-against-hfd-stz-induced-diabetic-kidney-disease
#20
JOURNAL ARTICLE
Mohamed Mohany, Mohammed M Ahmed, Salim S Al-Rejaie
LCZ696 (valsartan/sacubitril) has the potential to slow the progression of diabetic kidney disease (DKD) according to previous reports. However, the renoprotective mechanism underlying LCZ696 remains unknown. This study aimed to investigate the therapeutic potential and underlying mechanism of LCZ696 in DKD in a type 2 diabetic (T2D) rat model. This model was established in this experiment by feeding a high-fat diet (HFD) for six weeks with a single dose of streptozotocin (STZ, 30 mg/kg body weight). Valsartan or LCZ696 was orally administered to T2D animals for eight weeks...
November 9, 2022: Biomedicines
keyword
keyword
71572
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.